iDose TR is the first-of-its-kind, long duration, anchored intracameral procedural pharmaceutical therapy for the treatment of OAG or OHT. It delivers continuous prostaglandin analog therapy directly into the anterior chamber to help with long-term …

2024年3月26日 · iDose TR (travoprost) is a long-acting eye implant used for open-angle glaucoma or ocular hypertension to lower pressure within the eye. iDose TR works by slowly releasing travoprost, which increases the flow of a water-like fluid (aqueous humor) out of the eye, which decreases eye pressure (intraocular pressure).

2023年12月15日 · iDose TR是一种含有75毫克曲伏前列素的无菌前房植入物。 它是一种首创、持续时间长的前房内手术药物疗法，旨在长时间持续将药物输送到眼内。 该疗法旨在通过解决普遍存在的患者不依从性问题以及与局部青光眼药物相关的慢性副作用来提高护理标准。

iDose TR is a travoprost delivery system consisting of a travoprost releasing implant pre-loaded in a sterile, single-dose inserter. iDose TR is administered intracamerally through a small, clear corneal incision and is anchored into the sclera at the iridocorneal angle. iDose TR should not be readministered to an eye that received a prior ...

Learn about iDose® TR (travoprost intracameral implant) 75 mcg—the convenient, FDA-approved treatment that helps lower eye pressure in most people with open-angle glaucoma or high eye pressure (ocular hypertension); discover the benefits of taking a …

眼科医疗技术和制药公司Glaukos Corporation于12月14日宣布，美国食品药品监督管理局(FDA)已批准其前列腺素类似物iDose TR(曲伏前列素前房内植入物)75mcg的新药申请(NDA)，用于降低高眼压症(OHT)或开角型青光眼(OAG)患者的眼内压(IOP)。该产品预计将于2024年第一季度上市。

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). iDose TR delivers continuous long-term prostaglandin analog therapy directly into the anterior chamber for IOP control with proven safety and patient tolerability.

What is iDose TR? iDose TR is an FDA-approved, all-in-one prescription medicine and drug delivery system for lowering eye pressure. Barely visible to the human eye, iDose TR is a tiny implant specially designed to continuously release proven eye pressure-lowering medication directly inside your eye, where it’s needed most.

iDose TR is a procedural pharmaceutical that delivers prostaglandin analog therapy for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. First-of-kind anchored implant designed to deliver drug therapy with 24/7 adherence

2024年1月1日 · 近日，眼科医疗技术兼制药公司Glaukos（纽约证券交易所代码：GKOS）宣布FDA已批准新药申请（NDA），该公司装载75微克曲伏前列素前房的iDose ® TR植入物可用于治疗青光眼。